erlotinib hydrochloride has been researched along with Benign Supratentorial Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arvold, ND; Baumber, R; Berger, MS; Eberhard, DA; Haas-Kogan, DA; Jelluma, N; Kapadia, A; Lamborn, KR; Malec, M; Prados, MD; Stokoe, D; Tihan, T | 1 |
1 trial(s) available for erlotinib hydrochloride and Benign Supratentorial Neoplasms
| Article | Year |
|---|---|
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Supratentorial Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2005 |